Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-30

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

detect level of Inturlekin 33 in ankylosing spondyilits patient

measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients

detect the relation between IL33 and subclinical atherosclerosis in Ankylosinig Spondylitis patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Relationship Between Arterial Stiffness and Pulmonary and Extrapulmonary Features in Ankylosing Spondylitis

NCT06739369

Ankylosing Spondylitis (AS)

RECRUITING

Advanced Sensor Based Functional ASsessmenTs in Axial Spondyloarthritis

NCT04489342

Axial Spondyloarthritis

RECRUITING

Assessment of 14-3-3 η (Eta) Protein Antibodies in the Serum of Rheumatoid Arthritis Patients and Its Relation to Atherosclerosis.

NCT04937140

Rheumatoid Arthritis

UNKNOWN

Cardiovascular Disease Risk Factors and Healthy Lifestyle Behaviours in Patients with Ankylosing Spondylitis

NCT06650228

Ankylosing Spondylitis (AS)

RECRUITING

Comprehensive Assessment of Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis

NCT03813017

Cardiovascular Diseases Rheumatoid Arthritis Atherosclerosis, Coronary

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ankylosing spondylitis (AS), a type of SpA, is an autoimmune disease that mainly involves, sacroiliac joints (SIJs) and their adjacent soft tissues, such as tendons and ligaments. The main clinical manifestations include back pain and progressive spinal rigidity as well as inflammation of the hips, shoulders, peripheral joints and fingers/toes. In addition, there are extra-articular manifestations.

Cardiovascular disease has become the first cause of death for patients with ankylosing spondylitis (AS).

Patients with ankylosing spondylitis (AS) have an increased cardiovascular morbidity and mortality . Accelerated atherosclerosis caused by a systemic inflammatory response has been reported to be an important risk factor for increased cardiovascular risk for autoimmune diseases.

Interleukin (IL)-33 is a cytokine belonging to the IL-1 family and was recently identified as a ligand for ST2, .the serum levels of IL-33/sST2 were remarkably higher in the patients with AS than the healthy groups .

Pervious studies confirm the importance of IL-33/ST2 axis in the process of atherosclerosis, and indicate its ambiguous function in immune response, whether as proinflammatory cytokine in advanced atherosclerotic lesions, or as profibrotic, in early lesions.

Previous study shows increased CIMT in AS patients without traditional cardiovascular risk factors compared to healthy controls.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ankylosing Spondylitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ankylosing spondylities patients

detect level of IL33 in serum of AS patients

measure carotid intima media thickness by caroid dupex

carotid duplex

Intervention Type DEVICE

measure Carotid intima media thickness

control persons

detect level of IL33 in serum of normal control group

measure carotid intima media thickness by caroid dupex

carotid duplex

Intervention Type DEVICE

measure Carotid intima media thickness

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

carotid duplex

measure Carotid intima media thickness

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient diagnosed as Ankylosing Spondylitis
* Age (20-40)

Exclusion Criteria

* Patients with other rheumatic diseases/other SPA types

* Participants with history of CVD event in past or present
* Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
* Patient with other risk factor for atherosclerosis.

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes